tirzepatide vs semaglutide gi side effects caused roughly half as many patients to stop treatment because of gastrointestinal as semaglutide. In the first major head-to-head obesity trial, side effects caused treatment discontinuation in: Tirzepatide Tirzepatide vs Semaglutide 2026: 22%

Viral Immunol 34(10):722725

These include mono agonists, glucagonlike peptide-1 receptor agonists (GLP-1 agonists), and dual agonists that combine a glucose-dependent insulinotropic polypeptide (GIP) with a GLP-1 agonist (GIP/GLP-1), which have demonstrated a 15% and greater weight loss in people with obesity and/or type 2 diabetes, says Richard E

Dosing schedules may vary depending on patient goals, metabolic health, and physician guidance

Try using your TDEE estimate for 23 weeks to track your average intake and weight trend, and then fine-tune based on the results

Fewer injections means fewer opportunities for error

Cyclic nucleotide signaling in sensory neuron hyperexcitability and chronic pain after nerve injury, Neurobiol